Genotype-phenotype correlations in a large series of patients with muscle type CPT II deficiency
Authors:
- Marina FaninMFMarina Fanin
- Christine Vianey-SabanCVChristine Vianey-Saban
- Denise CassandriniDCDenise Cassandrini
- Chiara FiorilloCFChiara Fiorillo
- Claudio BrunoCBClaudio Bruno
- Corrado AngeliniCACorrado Angelini
- 1 January 2011
- journal article
- Published by Taylor & Francis in Neurological Research
- Vol. 33 (1) , 24-32
Abstract
The adult or 'muscular' form of carnitine-palmitoyl-transferase II (CPT II) deficiency presents with recurrent rhabdomyolytic episodes and myoglobinuria, usually triggered by prolonged exercise. The aim of this study was to investigate a large series of patients in order to provide genotype-phenotype correlations. Our muscle tissue bank was surveyed for patients showing attacks of rhabdomyolysis with myoglobinuria. After exclusion of cases affected with toxic myoglobinuria, McArdle's disease and Becker muscular dystrophy, over 100 patients were selected for isotope-exchange radioenzymatic assay of CPT enzyme activity in muscle, and 25 cases resulted to be defective. Acylcarnitine profile was performed in five patients using tandem mass spectrometry. Mutations in the CPT2 gene were identified using DNA sequencing. Although the clinical features were rather homogeneous, some patients presented life-threatening events (acute renal failure) and muscle weakness, and low levels of residual CPT activity. The typical acylcarnitine profile found in mutant patients confirmed its value as a screening method for further diagnostic investigations. We found a high frequency of the common p.Ser113Leu mutation, the recurrence of the rare p.Arg631Cys mutation in a genetic isolate in Southern Italy, and identified four novel mutations. In some affected patients only one mutant allele was found, suggesting either incomplete mutation detection or the possibility they are symptomatic carriers. Null mutations and homozygous mutations were frequently associated with a more severe phenotype and biochemical defect. The identification of symptomatic obligate heterozygous carriers might suggest that additional epigenetic or environmental factors may contribute to determine the phenotype.Keywords
This publication has 20 references indexed in Scilit:
- Bezafibrate for an Inborn Mitochondrial Beta-Oxidation DefectNew England Journal of Medicine, 2009
- Identification of the infant-type R631C mutation in patients with the benign muscular form of CPT2 deficiencyNeuromuscular Disorders, 2007
- Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspectsMolecular Aspects of Medicine, 2004
- Synergistic Heterozygosity: Disease Resulting from Multiple Partial Defects in One or More Metabolic PathwaysMolecular Genetics and Metabolism, 2000
- A Variable Myopathy Associated with Heterozygosity for the R503C Mutation in the Carnitine Palmitoyltransferase II GeneMolecular Genetics and Metabolism, 2000
- A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator- activated receptor alpha- deficient mice.Journal of Clinical Investigation, 1998
- Identification of a common mutation in the carnitine palmitoyltransferase II gene in familial recurrent myoglobinuria patientsNature Genetics, 1993
- Malonyl-CoA Abnormal Inhibition of Residual Enzyme Activity in Carnitine Palmitoyltransferase DeficiencyEuropean Neurology, 1986
- Acute rhabdomyolysis with carnitine-palmityl-transferase deficiencyIntensive Care Medicine, 1982
- Carnitine palmityl transferase deficiencyNeurology, 1980